APA (7th ed.) Citation

Goje, O., King, T., Angulo, D., & Azie, N. (2022). Oral Ibrexafungerp Outcomes in Subjects With Refractory Vulvovaginal Candidiasis From an Open-Label Study (FURI) [A122]. Obstetrics & Gynecology, 139, 36S. https://doi.org/10.1097/01.AOG.0000825768.79961.5b

Chicago Style (17th ed.) Citation

Goje, Oluwatosin, Thomas King, David Angulo, and Nkechi Azie. "Oral Ibrexafungerp Outcomes in Subjects With Refractory Vulvovaginal Candidiasis From an Open-Label Study (FURI) [A122]." Obstetrics & Gynecology 139 (2022): 36S. https://doi.org/10.1097/01.AOG.0000825768.79961.5b.

MLA (9th ed.) Citation

Goje, Oluwatosin, et al. "Oral Ibrexafungerp Outcomes in Subjects With Refractory Vulvovaginal Candidiasis From an Open-Label Study (FURI) [A122]." Obstetrics & Gynecology, vol. 139, 2022, p. 36S, https://doi.org/10.1097/01.AOG.0000825768.79961.5b.